{"gene":"AMELX","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1991,"finding":"A deletion extending over 5 kb of the amelogenin gene (AMELX/AMG) was identified in males with the hypomineralization form of X-linked amelogenesis imperfecta (AIH1), establishing that AMELX encodes a protein with a direct role in biomineralization of tooth enamel.","method":"Southern blot analysis, PCR analysis, segregation analysis in 15 individuals","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — Southern blot and PCR with segregation confirmed in 15 individuals from the same kindred; independently replicated in multiple subsequent studies","pmids":["1916828"],"is_preprint":false},{"year":1992,"finding":"A nonsense mutation (single base deletion in exon 5 causing frameshift and premature TGA stop codon) in AMELX was identified in an X-linked amelogenesis imperfecta family, resulting in both enamel hypoplasia and hypomineralization, indicating amelogenin is required for both normal enamel thickness and mineralization.","method":"DNA sequencing, PCR amplification of AMELX exons, clinical phenotyping","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mutation identification with phenotypic correlation; single lab but two complementary methods","pmids":["1483698"],"is_preprint":false},{"year":1995,"finding":"Three novel AMELX mutations were identified in X-linked amelogenesis imperfecta families: a C-T substitution in exon 5, a G-T substitution in exon 6, and a single cytosine deletion in exon 6, confirming extensive allelic heterogeneity and the direct role of AMELX in enamel biomineralization.","method":"Single-strand conformational polymorphism (SSCP) analysis and DNA sequencing","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (SSCP + sequencing) in three families, single lab","pmids":["7599636"],"is_preprint":false},{"year":2000,"finding":"A specific AMELX point mutation (C to A at codon 41) in a highly conserved region results in a consistent enamel phenotype: opaque enamel with prism defects, morphologically abnormal crystallites, retention of amelogenin protein within crystallites (not inter-crystalline spaces), and increased amelogenin-like protein content (0.95% vs 0.13% normal). This demonstrates that codon 41 encodes a residue critical for normal amelogenin function in enamel matrix organization.","method":"Mutational analysis by PCR and sequencing; light, scanning, and transmission electron microscopy; immunolocalization with anti-amelogenin antibodies; amino acid analysis","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (sequencing, multiple microscopy modalities, immunolocalization, biochemical analysis) in three families with consistent phenotype","pmids":["11005731"],"is_preprint":false},{"year":2010,"finding":"A missense mutation (Y→H substitution) in the tri-tyrosyl domain of mouse Amelx causes failure of ameloblasts to secrete full-length amelogenin, leading to engorgement of the ER/Golgi apparatus, increased ameloblast apoptosis, and severe enamel biomineralization defects. Co-transfection of mutant Amelx with Ambn in a eukaryotic cell line revealed intracellular abnormalities and increased cytotoxicity, suggesting protein-protein interactions mediated via the amelogenin tri-tyrosyl motif are mechanistically important.","method":"Mouse genetic model characterization; immunohistochemistry; co-transfection in eukaryotic cell line; multi-disciplinary histological and cell biological analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including in vivo mouse model, immunohistochemistry, and cell-based co-transfection assays; demonstrates secretion failure mechanism directly","pmids":["20067920"],"is_preprint":false},{"year":2016,"finding":"Amelogenin (encoded by Amelx) is required for thickening the enamel layer, organizing enamel ribbon development, and facilitating conversion of enamel ribbons from octacalcium phosphate into hydroxyapatite. In Amelx-null mice, enamel thickness was only 1/6th of wild type, nanohardness was less than half normal, enamel ribbons fused into plates, and the predominant mineral was octacalcium phosphate rather than hydroxyapatite. Amelx+/− mice showed lyonization-dependent enamel variation.","method":"RT-PCR, Western blotting, immunohistochemistry, transmission electron microscopy, scanning electron microscopy, nanohardness testing, X-ray diffraction; Amelx knockout mouse model","journal":"Molecular genetics & genomic medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal structural and biochemical methods in a genetic knockout model; direct demonstration of mineral conversion role","pmids":["27896287"],"is_preprint":false},{"year":2014,"finding":"A silent mutation in exon 4 of AMELX that causes inclusion of exon 4 (normally almost always skipped) in the mRNA transcript leads to enamel matrix mineralization defects. Transgenic animal modeling confirmed that alteration of the conserved alternative splicing repertoire of AMELX (ratio and quantity of isoforms) causes enamel defects, demonstrating that the specific pattern of AMELX alternative splicing is mechanistically required for normal enamel formation.","method":"Family recruitment, AMELX mutation identification, mRNA splice analysis, transgenic animal model generation and characterization","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 2 / Strong — human mutation identified, mechanistic consequence validated in transgenic animal model with multiple methods","pmids":["25117480"],"is_preprint":false}],"current_model":"AMELX encodes amelogenin, the most abundant enamel matrix protein, which is secreted by ameloblasts and functions as a resorbable extracellular matrix that organizes enamel crystal (ribbon) growth, promotes separation and maturation of enamel ribbons, and facilitates conversion of octacalcium phosphate into hydroxyapatite; loss-of-function mutations (deletions, frameshifts, missense mutations in the tri-tyrosyl domain, or disruption of conserved alternative splicing) abolish normal secretion or function of amelogenin, causing X-linked amelogenesis imperfecta with defects in enamel thickness, mineralization, and prism organization."},"narrative":{"mechanistic_narrative":"AMELX encodes amelogenin, an enamel matrix protein with a direct, non-redundant role in the biomineralization of tooth enamel [PMID:1916828, PMID:27896287]. Amelogenin secreted by ameloblasts organizes enamel ribbon development, drives thickening of the enamel layer, and facilitates conversion of the initial octacalcium phosphate mineral into hydroxyapatite; in Amelx-null enamel the layer is markedly thinned, ribbons fuse into plates, hardness is reduced, and octacalcium phosphate persists as the predominant mineral [PMID:27896287]. Normal function depends on the conserved tri-tyrosyl domain, where a Y→H substitution blocks secretion of full-length amelogenin, causing ER/Golgi engorgement, ameloblast apoptosis, and severe mineralization defects, and where the same motif mediates protein-protein interactions implicated in cytotoxicity when co-expressed with ameloblastin (Ambn) [PMID:20067920]. Function also requires the precise repertoire of AMELX alternative splicing: a silent exon 4 variant that forces inclusion of the normally skipped exon 4 disrupts the isoform ratio and produces enamel mineralization defects [PMID:25117480]. Loss-of-function lesions — large deletions, frameshift/nonsense mutations, and missense changes in conserved residues such as codon 41 — cause X-linked amelogenesis imperfecta with defects in enamel thickness, mineralization, and prism organization [PMID:1916828, PMID:1483698, PMID:11005731]; the codon 41 mutation specifically causes retention of amelogenin within crystallites and abnormal crystallite morphology, establishing this residue as critical for matrix organization [PMID:11005731].","teleology":[{"year":1991,"claim":"Established that AMELX itself is required for enamel biomineralization by linking a large gene deletion to the hypomineralization form of X-linked amelogenesis imperfecta.","evidence":"Southern blot, PCR, and segregation analysis across 15 individuals in a kindred","pmids":["1916828"],"confidence":"High","gaps":["Does not define which protein domains or functions are lost","No molecular mechanism of how amelogenin organizes mineral"]},{"year":1992,"claim":"Showed amelogenin is required for both enamel thickness and mineralization, not just one, by tying a frameshift/premature-stop mutation to a combined hypoplasia and hypomineralization phenotype.","evidence":"DNA sequencing and PCR of AMELX exons with clinical phenotyping in an AI family","pmids":["1483698"],"confidence":"Medium","gaps":["Single family, single lab","Does not distinguish secretion failure from downstream matrix dysfunction"]},{"year":1995,"claim":"Demonstrated extensive allelic heterogeneity in AMELX-linked amelogenesis imperfecta, reinforcing the gene's causal role across multiple distinct mutations.","evidence":"SSCP analysis and DNA sequencing in three AI families","pmids":["7599636"],"confidence":"Medium","gaps":["No functional characterization of the individual variants","Genotype-phenotype correlation not resolved at protein level"]},{"year":2000,"claim":"Identified a single conserved residue (codon 41) whose substitution disrupts matrix organization, showing amelogenin must reside in inter-crystalline spaces rather than be retained within crystallites for normal enamel.","evidence":"PCR/sequencing plus light/SEM/TEM microscopy, anti-amelogenin immunolocalization, and amino acid analysis in three families","pmids":["11005731"],"confidence":"High","gaps":["Mechanism by which codon 41 controls protein partitioning unknown","Does not address splicing or secretion"]},{"year":2010,"claim":"Defined a secretion-failure mechanism: the tri-tyrosyl domain is needed for ameloblasts to secrete full-length amelogenin, and its disruption causes ER/Golgi engorgement, apoptosis, and possibly toxic interactions with ameloblastin.","evidence":"Mouse Amelx Y→H genetic model with immunohistochemistry and co-transfection with Ambn in a eukaryotic cell line","pmids":["20067920"],"confidence":"High","gaps":["Direct binding between amelogenin and ameloblastin not biochemically demonstrated","Contribution of cell death versus matrix loss to phenotype not separated"]},{"year":2014,"claim":"Established that the conserved AMELX alternative-splicing pattern itself is functionally required, since forcing inclusion of normally skipped exon 4 disrupts isoform balance and causes mineralization defects.","evidence":"Human mutation identification, mRNA splice analysis, and transgenic animal modeling","pmids":["25117480"],"confidence":"High","gaps":["Distinct functional roles of individual isoforms not defined","How altered isoform ratio impairs mineralization at molecular level unclear"]},{"year":2016,"claim":"Resolved amelogenin's structural and chemical role in enamel: it thickens the layer, organizes ribbon separation, and drives conversion of octacalcium phosphate to hydroxyapatite, with dose-dependent (lyonization) effects.","evidence":"Amelx knockout/heterozygous mouse model with RT-PCR, Western blot, IHC, TEM/SEM, nanohardness testing, and X-ray diffraction","pmids":["27896287"],"confidence":"High","gaps":["Molecular mechanism of OCP-to-HAP conversion not defined","Direct biochemical interaction of amelogenin with mineral surfaces not characterized"]},{"year":null,"claim":"How amelogenin physically couples to other matrix proteins and mineral surfaces to template crystal growth, and the discrete functional division between its splice isoforms, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No direct structural model of amelogenin-mineral or amelogenin-ameloblastin interaction in the corpus","Isoform-specific functions not assigned"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[3,5]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[3,5]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,5]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[3,5]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,5]}],"complexes":[],"partners":["AMBN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99217","full_name":"Amelogenin, X isoform","aliases":[],"length_aa":191,"mass_kda":21.6,"function":"Plays a role in biomineralization. Seems to regulate the formation of crystallites during the secretory stage of tooth enamel development. Thought to play a major role in the structural organization and mineralization of developing enamel","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q99217/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AMELX","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AMELX","total_profiled":1310},"omim":[{"mim_id":"613214","title":"WD REPEAT-CONTAINING PROTEIN 72; WDR72","url":"https://www.omim.org/entry/613214"},{"mim_id":"612090","title":"MICRO RNA 200A; MIR200A","url":"https://www.omim.org/entry/612090"},{"mim_id":"610912","title":"AMELOTIN; AMTN","url":"https://www.omim.org/entry/610912"},{"mim_id":"606585","title":"ENAMELIN; ENAM","url":"https://www.omim.org/entry/606585"},{"mim_id":"601542","title":"PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 2; PITX2","url":"https://www.omim.org/entry/601542"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AMELX"},"hgnc":{"alias_symbol":[],"prev_symbol":["AMG","AIH1"]},"alphafold":{"accession":"Q99217","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99217","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99217-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99217-F1-predicted_aligned_error_v6.png","plddt_mean":59.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AMELX","jax_strain_url":"https://www.jax.org/strain/search?query=AMELX"},"sequence":{"accession":"Q99217","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99217.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99217/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99217"}},"corpus_meta":[{"pmid":"31666701","id":"PMC_31666701","title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31666701","citation_count":1770,"is_preprint":false},{"pmid":"20593411","id":"PMC_20593411","title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.","date":"2011","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20593411","citation_count":611,"is_preprint":false},{"pmid":"17050891","id":"PMC_17050891","title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.","date":"2006","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17050891","citation_count":391,"is_preprint":false},{"pmid":"30254093","id":"PMC_30254093","title":"AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/30254093","citation_count":340,"is_preprint":false},{"pmid":"15615864","id":"PMC_15615864","title":"AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.","date":"2004","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15615864","citation_count":325,"is_preprint":false},{"pmid":"24014831","id":"PMC_24014831","title":"Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.","date":"2013","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/24014831","citation_count":283,"is_preprint":false},{"pmid":"26879279","id":"PMC_26879279","title":"Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.","date":"2016","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26879279","citation_count":275,"is_preprint":false},{"pmid":"16951187","id":"PMC_16951187","title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16951187","citation_count":262,"is_preprint":false},{"pmid":"19786654","id":"PMC_19786654","title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19786654","citation_count":257,"is_preprint":false},{"pmid":"31895611","id":"PMC_31895611","title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.","date":"2020","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31895611","citation_count":250,"is_preprint":false},{"pmid":"1916828","id":"PMC_1916828","title":"A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1).","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1916828","citation_count":245,"is_preprint":false},{"pmid":"15592334","id":"PMC_15592334","title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.","date":"2004","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15592334","citation_count":231,"is_preprint":false},{"pmid":"26239198","id":"PMC_26239198","title":"Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26239198","citation_count":215,"is_preprint":false},{"pmid":"19546406","id":"PMC_19546406","title":"Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19546406","citation_count":203,"is_preprint":false},{"pmid":"33203642","id":"PMC_33203642","title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33203642","citation_count":200,"is_preprint":false},{"pmid":"12595492","id":"PMC_12595492","title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.","date":"2003","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/12595492","citation_count":199,"is_preprint":false},{"pmid":"12472790","id":"PMC_12472790","title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.","date":"2003","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12472790","citation_count":171,"is_preprint":false},{"pmid":"28655795","id":"PMC_28655795","title":"First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28655795","citation_count":170,"is_preprint":false},{"pmid":"22700995","id":"PMC_22700995","title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.","date":"2012","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22700995","citation_count":166,"is_preprint":false},{"pmid":"26559125","id":"PMC_26559125","title":"Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.","date":"2015","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26559125","citation_count":166,"is_preprint":false},{"pmid":"24300852","id":"PMC_24300852","title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24300852","citation_count":166,"is_preprint":false},{"pmid":"17557949","id":"PMC_17557949","title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17557949","citation_count":159,"is_preprint":false},{"pmid":"24311721","id":"PMC_24311721","title":"Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24311721","citation_count":146,"is_preprint":false},{"pmid":"25043603","id":"PMC_25043603","title":"Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/25043603","citation_count":141,"is_preprint":false},{"pmid":"20937592","id":"PMC_20937592","title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20937592","citation_count":129,"is_preprint":false},{"pmid":"25567130","id":"PMC_25567130","title":"The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.","date":"2015","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25567130","citation_count":127,"is_preprint":false},{"pmid":"19366899","id":"PMC_19366899","title":"AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.","date":"2009","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19366899","citation_count":120,"is_preprint":false},{"pmid":"18006775","id":"PMC_18006775","title":"AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18006775","citation_count":118,"is_preprint":false},{"pmid":"24674885","id":"PMC_24674885","title":"Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24674885","citation_count":115,"is_preprint":false},{"pmid":"1483698","id":"PMC_1483698","title":"Identification of a nonsense mutation in the amelogenin gene (AMELX) in a family with X-linked amelogenesis imperfecta (AIH1).","date":"1992","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1483698","citation_count":114,"is_preprint":false},{"pmid":"30918018","id":"PMC_30918018","title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30918018","citation_count":112,"is_preprint":false},{"pmid":"20935223","id":"PMC_20935223","title":"Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20935223","citation_count":108,"is_preprint":false},{"pmid":"31359240","id":"PMC_31359240","title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.","date":"2019","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/31359240","citation_count":108,"is_preprint":false},{"pmid":"33046621","id":"PMC_33046621","title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33046621","citation_count":105,"is_preprint":false},{"pmid":"7599636","id":"PMC_7599636","title":"Characterisation of molecular defects in X-linked amelogenesis imperfecta (AIH1).","date":"1995","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/7599636","citation_count":102,"is_preprint":false},{"pmid":"18214948","id":"PMC_18214948","title":"The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics.","date":"2008","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18214948","citation_count":100,"is_preprint":false},{"pmid":"24967612","id":"PMC_24967612","title":"Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24967612","citation_count":94,"is_preprint":false},{"pmid":"33231489","id":"PMC_33231489","title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.","date":"2020","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/33231489","citation_count":93,"is_preprint":false},{"pmid":"22692704","id":"PMC_22692704","title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.","date":"2012","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22692704","citation_count":92,"is_preprint":false},{"pmid":"31253596","id":"PMC_31253596","title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31253596","citation_count":89,"is_preprint":false},{"pmid":"39293516","id":"PMC_39293516","title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.","date":"2024","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39293516","citation_count":85,"is_preprint":false},{"pmid":"25931519","id":"PMC_25931519","title":"AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.","date":"2015","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25931519","citation_count":82,"is_preprint":false},{"pmid":"22087278","id":"PMC_22087278","title":"AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22087278","citation_count":80,"is_preprint":false},{"pmid":"23174659","id":"PMC_23174659","title":"Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.","date":"2012","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23174659","citation_count":79,"is_preprint":false},{"pmid":"20124448","id":"PMC_20124448","title":"Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20124448","citation_count":75,"is_preprint":false},{"pmid":"33504551","id":"PMC_33504551","title":"The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33504551","citation_count":73,"is_preprint":false},{"pmid":"28593473","id":"PMC_28593473","title":"Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.","date":"2017","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/28593473","citation_count":71,"is_preprint":false},{"pmid":"11005731","id":"PMC_11005731","title":"Unique enamel phenotype associated with amelogenin gene (AMELX) codon 41 point mutation.","date":"2000","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/11005731","citation_count":70,"is_preprint":false},{"pmid":"30253804","id":"PMC_30253804","title":"Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.","date":"2018","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30253804","citation_count":70,"is_preprint":false},{"pmid":"26295610","id":"PMC_26295610","title":"T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.","date":"2015","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/26295610","citation_count":69,"is_preprint":false},{"pmid":"21385891","id":"PMC_21385891","title":"Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.","date":"2011","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21385891","citation_count":67,"is_preprint":false},{"pmid":"32655895","id":"PMC_32655895","title":"AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.","date":"2020","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32655895","citation_count":64,"is_preprint":false},{"pmid":"24641103","id":"PMC_24641103","title":"Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24641103","citation_count":63,"is_preprint":false},{"pmid":"26290606","id":"PMC_26290606","title":"Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.","date":"2015","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26290606","citation_count":63,"is_preprint":false},{"pmid":"39282709","id":"PMC_39282709","title":"AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers.","date":"2025","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39282709","citation_count":58,"is_preprint":false},{"pmid":"25824308","id":"PMC_25824308","title":"Evolocumab (AMG 145) for primary hypercholesterolemia.","date":"2015","source":"Expert review of cardiovascular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25824308","citation_count":58,"is_preprint":false},{"pmid":"29018537","id":"PMC_29018537","title":"Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.","date":"2017","source":"Lupus science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29018537","citation_count":57,"is_preprint":false},{"pmid":"21156020","id":"PMC_21156020","title":"A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.","date":"2010","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/21156020","citation_count":55,"is_preprint":false},{"pmid":"23108953","id":"PMC_23108953","title":"Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.","date":"2012","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23108953","citation_count":55,"is_preprint":false},{"pmid":"32898244","id":"PMC_32898244","title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32898244","citation_count":54,"is_preprint":false},{"pmid":"24235081","id":"PMC_24235081","title":"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.","date":"2013","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/24235081","citation_count":53,"is_preprint":false},{"pmid":"26305211","id":"PMC_26305211","title":"The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26305211","citation_count":53,"is_preprint":false},{"pmid":"23903371","id":"PMC_23903371","title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.","date":"2013","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/23903371","citation_count":51,"is_preprint":false},{"pmid":"22221294","id":"PMC_22221294","title":"MBL2, MASP2, AMELX, and ENAM gene polymorphisms and dental caries in Polish children.","date":"2012","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22221294","citation_count":50,"is_preprint":false},{"pmid":"31937611","id":"PMC_31937611","title":"AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31937611","citation_count":49,"is_preprint":false},{"pmid":"26304872","id":"PMC_26304872","title":"Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26304872","citation_count":48,"is_preprint":false},{"pmid":"26290435","id":"PMC_26290435","title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \"peptibody\" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.","date":"2015","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26290435","citation_count":47,"is_preprint":false},{"pmid":"23990115","id":"PMC_23990115","title":"AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23990115","citation_count":46,"is_preprint":false},{"pmid":"27196782","id":"PMC_27196782","title":"In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27196782","citation_count":45,"is_preprint":false},{"pmid":"31154523","id":"PMC_31154523","title":"Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.","date":"2019","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31154523","citation_count":45,"is_preprint":false},{"pmid":"37861452","id":"PMC_37861452","title":"AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37861452","citation_count":44,"is_preprint":false},{"pmid":"21114591","id":"PMC_21114591","title":"Association between AMELX polymorphisms and dental caries in Koreans.","date":"2010","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21114591","citation_count":44,"is_preprint":false},{"pmid":"30745297","id":"PMC_30745297","title":"89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30745297","citation_count":43,"is_preprint":false},{"pmid":"24727326","id":"PMC_24727326","title":"Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24727326","citation_count":43,"is_preprint":false},{"pmid":"20677100","id":"PMC_20677100","title":"AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.","date":"2010","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20677100","citation_count":42,"is_preprint":false},{"pmid":"25747197","id":"PMC_25747197","title":"Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.","date":"2015","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/25747197","citation_count":42,"is_preprint":false},{"pmid":"32886754","id":"PMC_32886754","title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32886754","citation_count":41,"is_preprint":false},{"pmid":"21161195","id":"PMC_21161195","title":"Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells.","date":"2010","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/21161195","citation_count":41,"is_preprint":false},{"pmid":"34675734","id":"PMC_34675734","title":"Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer.","date":"2021","source":"Lung Cancer (Auckland, N.Z.)","url":"https://pubmed.ncbi.nlm.nih.gov/34675734","citation_count":40,"is_preprint":false},{"pmid":"25213774","id":"PMC_25213774","title":"Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.","date":"2014","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/25213774","citation_count":40,"is_preprint":false},{"pmid":"26434934","id":"PMC_26434934","title":"AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.","date":"2015","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26434934","citation_count":40,"is_preprint":false},{"pmid":"27896287","id":"PMC_27896287","title":"Enamel ribbons, surface nodules, and octacalcium phosphate in C57BL/6 Amelx mice and Amelx lyonization.","date":"2016","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27896287","citation_count":39,"is_preprint":false},{"pmid":"31189530","id":"PMC_31189530","title":"AMG 510 First to Inhibit \"Undruggable\" KRAS.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31189530","citation_count":39,"is_preprint":false},{"pmid":"29980894","id":"PMC_29980894","title":"A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.","date":"2018","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29980894","citation_count":39,"is_preprint":false},{"pmid":"25363711","id":"PMC_25363711","title":"Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25363711","citation_count":37,"is_preprint":false},{"pmid":"19321594","id":"PMC_19321594","title":"The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats.","date":"2009","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19321594","citation_count":37,"is_preprint":false},{"pmid":"20067920","id":"PMC_20067920","title":"A mutation in the mouse Amelx tri-tyrosyl domain results in impaired secretion of amelogenin and phenocopies human X-linked amelogenesis imperfecta.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20067920","citation_count":36,"is_preprint":false},{"pmid":"8321016","id":"PMC_8321016","title":"Technical aspects of acoustic myography (AMG) of human skeletal muscle: contact pressure and force/AMG relationships.","date":"1993","source":"Journal of neuroscience methods","url":"https://pubmed.ncbi.nlm.nih.gov/8321016","citation_count":36,"is_preprint":false},{"pmid":"25970324","id":"PMC_25970324","title":"Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25970324","citation_count":36,"is_preprint":false},{"pmid":"25117480","id":"PMC_25117480","title":"Alteration of conserved alternative splicing in AMELX causes enamel defects.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25117480","citation_count":35,"is_preprint":false},{"pmid":"37694295","id":"PMC_37694295","title":"Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC).","date":"2023","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37694295","citation_count":34,"is_preprint":false},{"pmid":"21114421","id":"PMC_21114421","title":"Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.","date":"2010","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21114421","citation_count":34,"is_preprint":false},{"pmid":"28472537","id":"PMC_28472537","title":"Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.","date":"2017","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28472537","citation_count":34,"is_preprint":false},{"pmid":"22517972","id":"PMC_22517972","title":"Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.","date":"2012","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/22517972","citation_count":34,"is_preprint":false},{"pmid":"24526162","id":"PMC_24526162","title":"Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24526162","citation_count":33,"is_preprint":false},{"pmid":"32686745","id":"PMC_32686745","title":"KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32686745","citation_count":32,"is_preprint":false},{"pmid":"24361733","id":"PMC_24361733","title":"A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.","date":"2013","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24361733","citation_count":31,"is_preprint":false},{"pmid":"28370201","id":"PMC_28370201","title":"A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.","date":"2017","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28370201","citation_count":31,"is_preprint":false},{"pmid":"31366221","id":"PMC_31366221","title":"Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.","date":"2019","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/31366221","citation_count":30,"is_preprint":false},{"pmid":"24803302","id":"PMC_24803302","title":"Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.","date":"2014","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24803302","citation_count":30,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58964,"output_tokens":1871,"usd":0.102479,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8846,"output_tokens":2594,"usd":0.05454,"stage2_stop_reason":"end_turn"},"total_usd":0.157019,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"A deletion extending over 5 kb of the amelogenin gene (AMELX/AMG) was identified in males with the hypomineralization form of X-linked amelogenesis imperfecta (AIH1), establishing that AMELX encodes a protein with a direct role in biomineralization of tooth enamel.\",\n      \"method\": \"Southern blot analysis, PCR analysis, segregation analysis in 15 individuals\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Southern blot and PCR with segregation confirmed in 15 individuals from the same kindred; independently replicated in multiple subsequent studies\",\n      \"pmids\": [\"1916828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"A nonsense mutation (single base deletion in exon 5 causing frameshift and premature TGA stop codon) in AMELX was identified in an X-linked amelogenesis imperfecta family, resulting in both enamel hypoplasia and hypomineralization, indicating amelogenin is required for both normal enamel thickness and mineralization.\",\n      \"method\": \"DNA sequencing, PCR amplification of AMELX exons, clinical phenotyping\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mutation identification with phenotypic correlation; single lab but two complementary methods\",\n      \"pmids\": [\"1483698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Three novel AMELX mutations were identified in X-linked amelogenesis imperfecta families: a C-T substitution in exon 5, a G-T substitution in exon 6, and a single cytosine deletion in exon 6, confirming extensive allelic heterogeneity and the direct role of AMELX in enamel biomineralization.\",\n      \"method\": \"Single-strand conformational polymorphism (SSCP) analysis and DNA sequencing\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (SSCP + sequencing) in three families, single lab\",\n      \"pmids\": [\"7599636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A specific AMELX point mutation (C to A at codon 41) in a highly conserved region results in a consistent enamel phenotype: opaque enamel with prism defects, morphologically abnormal crystallites, retention of amelogenin protein within crystallites (not inter-crystalline spaces), and increased amelogenin-like protein content (0.95% vs 0.13% normal). This demonstrates that codon 41 encodes a residue critical for normal amelogenin function in enamel matrix organization.\",\n      \"method\": \"Mutational analysis by PCR and sequencing; light, scanning, and transmission electron microscopy; immunolocalization with anti-amelogenin antibodies; amino acid analysis\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (sequencing, multiple microscopy modalities, immunolocalization, biochemical analysis) in three families with consistent phenotype\",\n      \"pmids\": [\"11005731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A missense mutation (Y→H substitution) in the tri-tyrosyl domain of mouse Amelx causes failure of ameloblasts to secrete full-length amelogenin, leading to engorgement of the ER/Golgi apparatus, increased ameloblast apoptosis, and severe enamel biomineralization defects. Co-transfection of mutant Amelx with Ambn in a eukaryotic cell line revealed intracellular abnormalities and increased cytotoxicity, suggesting protein-protein interactions mediated via the amelogenin tri-tyrosyl motif are mechanistically important.\",\n      \"method\": \"Mouse genetic model characterization; immunohistochemistry; co-transfection in eukaryotic cell line; multi-disciplinary histological and cell biological analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including in vivo mouse model, immunohistochemistry, and cell-based co-transfection assays; demonstrates secretion failure mechanism directly\",\n      \"pmids\": [\"20067920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Amelogenin (encoded by Amelx) is required for thickening the enamel layer, organizing enamel ribbon development, and facilitating conversion of enamel ribbons from octacalcium phosphate into hydroxyapatite. In Amelx-null mice, enamel thickness was only 1/6th of wild type, nanohardness was less than half normal, enamel ribbons fused into plates, and the predominant mineral was octacalcium phosphate rather than hydroxyapatite. Amelx+/− mice showed lyonization-dependent enamel variation.\",\n      \"method\": \"RT-PCR, Western blotting, immunohistochemistry, transmission electron microscopy, scanning electron microscopy, nanohardness testing, X-ray diffraction; Amelx knockout mouse model\",\n      \"journal\": \"Molecular genetics & genomic medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal structural and biochemical methods in a genetic knockout model; direct demonstration of mineral conversion role\",\n      \"pmids\": [\"27896287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A silent mutation in exon 4 of AMELX that causes inclusion of exon 4 (normally almost always skipped) in the mRNA transcript leads to enamel matrix mineralization defects. Transgenic animal modeling confirmed that alteration of the conserved alternative splicing repertoire of AMELX (ratio and quantity of isoforms) causes enamel defects, demonstrating that the specific pattern of AMELX alternative splicing is mechanistically required for normal enamel formation.\",\n      \"method\": \"Family recruitment, AMELX mutation identification, mRNA splice analysis, transgenic animal model generation and characterization\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human mutation identified, mechanistic consequence validated in transgenic animal model with multiple methods\",\n      \"pmids\": [\"25117480\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AMELX encodes amelogenin, the most abundant enamel matrix protein, which is secreted by ameloblasts and functions as a resorbable extracellular matrix that organizes enamel crystal (ribbon) growth, promotes separation and maturation of enamel ribbons, and facilitates conversion of octacalcium phosphate into hydroxyapatite; loss-of-function mutations (deletions, frameshifts, missense mutations in the tri-tyrosyl domain, or disruption of conserved alternative splicing) abolish normal secretion or function of amelogenin, causing X-linked amelogenesis imperfecta with defects in enamel thickness, mineralization, and prism organization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AMELX encodes amelogenin, an enamel matrix protein with a direct, non-redundant role in the biomineralization of tooth enamel [#0, #5]. Amelogenin secreted by ameloblasts organizes enamel ribbon development, drives thickening of the enamel layer, and facilitates conversion of the initial octacalcium phosphate mineral into hydroxyapatite; in Amelx-null enamel the layer is markedly thinned, ribbons fuse into plates, hardness is reduced, and octacalcium phosphate persists as the predominant mineral [#5]. Normal function depends on the conserved tri-tyrosyl domain, where a Y→H substitution blocks secretion of full-length amelogenin, causing ER/Golgi engorgement, ameloblast apoptosis, and severe mineralization defects, and where the same motif mediates protein-protein interactions implicated in cytotoxicity when co-expressed with ameloblastin (Ambn) [#4]. Function also requires the precise repertoire of AMELX alternative splicing: a silent exon 4 variant that forces inclusion of the normally skipped exon 4 disrupts the isoform ratio and produces enamel mineralization defects [#6]. Loss-of-function lesions — large deletions, frameshift/nonsense mutations, and missense changes in conserved residues such as codon 41 — cause X-linked amelogenesis imperfecta with defects in enamel thickness, mineralization, and prism organization [#0, #1, #3]; the codon 41 mutation specifically causes retention of amelogenin within crystallites and abnormal crystallite morphology, establishing this residue as critical for matrix organization [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established that AMELX itself is required for enamel biomineralization by linking a large gene deletion to the hypomineralization form of X-linked amelogenesis imperfecta.\",\n      \"evidence\": \"Southern blot, PCR, and segregation analysis across 15 individuals in a kindred\",\n      \"pmids\": [\"1916828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define which protein domains or functions are lost\", \"No molecular mechanism of how amelogenin organizes mineral\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed amelogenin is required for both enamel thickness and mineralization, not just one, by tying a frameshift/premature-stop mutation to a combined hypoplasia and hypomineralization phenotype.\",\n      \"evidence\": \"DNA sequencing and PCR of AMELX exons with clinical phenotyping in an AI family\",\n      \"pmids\": [\"1483698\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family, single lab\", \"Does not distinguish secretion failure from downstream matrix dysfunction\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated extensive allelic heterogeneity in AMELX-linked amelogenesis imperfecta, reinforcing the gene's causal role across multiple distinct mutations.\",\n      \"evidence\": \"SSCP analysis and DNA sequencing in three AI families\",\n      \"pmids\": [\"7599636\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional characterization of the individual variants\", \"Genotype-phenotype correlation not resolved at protein level\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified a single conserved residue (codon 41) whose substitution disrupts matrix organization, showing amelogenin must reside in inter-crystalline spaces rather than be retained within crystallites for normal enamel.\",\n      \"evidence\": \"PCR/sequencing plus light/SEM/TEM microscopy, anti-amelogenin immunolocalization, and amino acid analysis in three families\",\n      \"pmids\": [\"11005731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which codon 41 controls protein partitioning unknown\", \"Does not address splicing or secretion\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a secretion-failure mechanism: the tri-tyrosyl domain is needed for ameloblasts to secrete full-length amelogenin, and its disruption causes ER/Golgi engorgement, apoptosis, and possibly toxic interactions with ameloblastin.\",\n      \"evidence\": \"Mouse Amelx Y→H genetic model with immunohistochemistry and co-transfection with Ambn in a eukaryotic cell line\",\n      \"pmids\": [\"20067920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding between amelogenin and ameloblastin not biochemically demonstrated\", \"Contribution of cell death versus matrix loss to phenotype not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that the conserved AMELX alternative-splicing pattern itself is functionally required, since forcing inclusion of normally skipped exon 4 disrupts isoform balance and causes mineralization defects.\",\n      \"evidence\": \"Human mutation identification, mRNA splice analysis, and transgenic animal modeling\",\n      \"pmids\": [\"25117480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct functional roles of individual isoforms not defined\", \"How altered isoform ratio impairs mineralization at molecular level unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved amelogenin's structural and chemical role in enamel: it thickens the layer, organizes ribbon separation, and drives conversion of octacalcium phosphate to hydroxyapatite, with dose-dependent (lyonization) effects.\",\n      \"evidence\": \"Amelx knockout/heterozygous mouse model with RT-PCR, Western blot, IHC, TEM/SEM, nanohardness testing, and X-ray diffraction\",\n      \"pmids\": [\"27896287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of OCP-to-HAP conversion not defined\", \"Direct biochemical interaction of amelogenin with mineral surfaces not characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How amelogenin physically couples to other matrix proteins and mineral surfaces to template crystal growth, and the discrete functional division between its splice isoforms, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No direct structural model of amelogenin-mineral or amelogenin-ameloblastin interaction in the corpus\", \"Isoform-specific functions not assigned\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AMBN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}